Skip to main content

Table 2 2 L chemotherapy

From: Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer

Therapy, n (%)a

Australia (N = 34)

Canada (N = 100)

Italy (N = 84)

UK (N = 62)

Overall (N = 280)

Monotherapy

20 (58.8%)

48 (48.0%)

38 (45.2%)

39 (62.9%)

145 (51.8%)

Combination therapyb

14 (41.2%)

52 (52.0%)

46 (54.8%)

23 (37.1%)

135 (48.2%)

 Doublet chemotherapy

10 (71.4%)

39 (75.0%)

38 (82.6%)

15 (65.2%)

102 (75.6%)

 Triplet chemotherapy

4 (28.6%)

13 (25.0%)

8 (17.4%)

7 (30.4%)

32 (23.7%)

Monotherapyc

 Taxanes

10 (50.0%)

23 (47.9%)

29 (76.3%)

38 (97.4%)

100 (69.0%)

 Irinotecan

6 (30.0%)

21 (43.8%)

4 (10.5%)

1 (2.6%)

32 (22.1%)

 Fluoropyrimidines

2 (10.0%)

3 (6.3%)

1 (2.6%)

-

6 (4.1%)

 Ramucirumab

-

1 (2.1%)

3 (7.9%)

-

4 (2.8%)

 Platinum

1 (5.0%)

-

1 (2.6%)

-

2 (1.4%)

 Other monotherapy

1 (5.0%)

-

-

-

1 (0.7%)

Doublet chemotherapyc

 Fluoropyrimidine + irinotecan

2 (14.3%)

25 (48.1%)

18 (39.1%)

-

45 (33.3%)

 Fluoropyrimidine + platinum

5 (35.7%)

6 (11.5%)

4 (8.7%)

9 (39.1%)

24 (17.8%)

 Taxanes + ramucirumab

-

2 (3.8%)

10 (21.7%)

1 (4.3%)

13 (9.6%)

 Taxanes + trastuzumab

-

-

3 (6.5%)

2 (8.7%)

5 (3.7%)

 Other doublet

3 (21.4%)

6 (11.5%)

3 (6.5%)

3 (13.0%)

15 (11.1%)

Triplet chemotherapyc

 

 Fluoropyrimidine + platinum + anthracycline

4 (28.6%)

5 (9.6%)

3 (6.5%)

3 (13.0%)

15 (11.1%)

 Fluoropyrimidine + platinum + other

-

8 (15.4%)

5 (10.9%)

2 (8.7%)

15 (11.1%)

 Other triplet

-

-

-

2 (8.7%)

2 (1.5%)

  1. a Specific drugs used are tabulated in the supplementary material
  2. b Percentages receiving doublet and triplet are out of number of patients who received combination therapy
  3. c Percentages for individual regimens are out of number of patients who received monotherapy or combination therapy, respectively